This Medudy course is a video tutorial for physicians on the topic of “The Capla 1000+ Project.” The format used here is what is known as a “Journal Club Summary,” in which we summarize individual studies for you.
Caplacizumab is a monoclonal nanobody that inhibits the binding of platelets to von Willebrand factor and has been approved since 2018 for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In this video, Professor Jörg Latus, Head of the Department of Internal Medicine and Nephrology at Robert Bosch Hospital in Stuttgart, presents the results of the Capla 1000+ project, an international cohort study on caplacizumab in a real-world setting.
Note: All “speakers” appearing in the Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. The video content was created and reviewed by the editorial team with the aid of AI, based on high-quality scientific sources, and has been approved by the speakers.
This course was developed with the kind support of Sanofi.
By the end of this course, you will know:
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
